Document is current

Article History

Received: 15 February 2022

Accepted: 23 May 2023

First Online: 19 June 2023

Declarations

:

: This study is conducted in agreement with either the Declaration of Helsinki (in its current version) or the laws and regulations in its current version. The protocol was written, and the study will be conducted according to the ICH Harmonized Tripartite Guideline for Good Clinical Practice. The protocol is approved by the independent ethics committee of the faculty for medicine from the Technische Universität Munich. Before a patient can participate in the trial, he must provide written informed consent. All patients will be informed about the aims of the trial, the possible adverse events and benefits, the procedures and possible risks, the treatment, alternative treatments and the insurance protection.

: Not applicable

: SL received institutional research grants from Bristol-Myers Squibb and Lilly and serves as an advisory board member for Merck, Bristol-Myers Squibb, Merck Sharp and Dohme, Servier, Sanofi and Amgen. MS is an advisory board member for Bristol-Myers Squibb, Lilly, MSD and is a speaker for Bristol-Myers Squibb, Lilly, MSD and Roche. MM received institutional research grants from Bristol-Myers Squibb, Merck, MSD and Amgen and serves as an advisory board member and speaker for Bristol-Myers Squibb, Merck Sharp and Dohme, Servier, Sanofi, Amgen, Lilly, Pfizer and Taiho. All the other authors declare no competing interests.